Literature DB >> 30927515

Assessing Rheumatoid Arthritis Disease Activity With Patient-Reported Outcomes Measurement Information System Measures Using Digital Technology.

Huifeng Yun1, W Benjamin Nowell2, David Curtis2, James H Willig1, Shuo Yang1, Matthew Auriemma1, Lang Chen1, Cooper Filby1, Jeffrey R Curtis1.   

Abstract

OBJECTIVE: Health information technology has enabled efficient measurement of patient-reported outcomes (PROs). The National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) is becoming more widely adopted for research and routine care, and some PROMIS instruments might be substituted for lengthier, legacy PRO instruments.
METHODS: Four PROMIS computer-adaptive testing (CAT) instruments (pain interference, physical function, sleep disturbance, and fatigue) and the Routine Assessment of Patient Index Data 3 (RAPID3), along with pain intensity and patient global assessment score, were administered to participants in the ArthritisPower registry. The RAPID3 was predicted using different combinations of these variables to create a new score (CAT-PROMIS RAPID3). Kappa statistics and Bland-Altman 95% limits of agreement were used to measure agreement between the observed versus predicted RAPID3.
RESULTS: A total of 6,154 eligible patients contributed 11,275 observations. The mean ± SD age was 52.7 ± 10.5 years, and 93% of patients were women. The median assessment times ranged from 29 seconds (PROMIS sleep disturbance) to 116 seconds (RAPID3). As single pairwise comparisons, the PROMIS CATs examined were modestly correlated (r approximately 0.4-0.7) to one other and RAPID3. Together with the pain intensity and patient global assessment, the PROMIS instruments explained a high fraction of total variance (R2 = 0.97) of the RAPID3 score. In the model with the highest agreement (κ = 0.93) between the observed RAPID3 and the CAT-PROMIS predicted RAPID3, Bland-Altman 95% limits of agreement showed minimal residual differences and no systematic biases.
CONCLUSION: There was excellent agreement between the observed RAPID3 and predicted RAPID3 scores estimated using several PROMIS instruments. The Multidimensional Health Assessment Questionnaire and patient global assessment components of RAPID3 may be unnecessary if PROMIS scores are available.
© 2019, American College of Rheumatology.

Entities:  

Year:  2020        PMID: 30927515     DOI: 10.1002/acr.23888

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  3 in total

Review 1.  Using Registry Data to Understand Disease Evolution in Inflammatory Myositis and Other Rheumatic Diseases.

Authors:  Lily Siok Hoon Lim; Brian M Feldman
Journal:  Curr Rheumatol Rep       Date:  2019-12-12       Impact factor: 4.592

2.  Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower.

Authors:  W Benjamin Nowell; Kelly Gavigan; Carol L Kannowski; Zhihong Cai; Theresa Hunter; Shilpa Venkatachalam; Julie Birt; Jennifer Workman; Jeffrey R Curtis
Journal:  Arthritis Res Ther       Date:  2021-02-10       Impact factor: 5.156

3.  Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions.

Authors:  W Benjamin Nowell; Peter A Merkel; Robert N McBurney; Kalen Young; Shilpa Venkatachalam; Dianne G Shaw; Angela Dobes; Emily Cerciello; Laura Kolaczkowski; Jeffrey R Curtis; Michael D Kappelman
Journal:  Patient       Date:  2021-04-27       Impact factor: 3.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.